The USPTO issued Patent No. US12590137B2 to the City of Hope National Medical Center, granting intellectual property protection for Meditope-enabled T cell compositions. The patented technology involves recombinant proteins that, when expressed by T cells, can recruit therapeutic antibodies to their target sites while reducing off-target effects. The patent contains 18 claims and names inventors John C. Williams, Christine Brown, Kurt Jenkins, Yi-Chiu Kuo, and Cheng-Fu Kuo.\n\nThis patent grant does not impose regulatory compliance obligations on third parties. However, entities developing T cell therapies, CAR-T products, or antibody-drug combinations should review these claims to assess potential freedom-to-operate implications. The technology may be relevant to companies in the cell therapy, immunotherapy, or targeted antibody sectors seeking to avoid infringement or explore licensing opportunities.